Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Conditions
Interventions
Ceritinib
Locations
23
United States
Dana Farber Cancer Institute Dept of Onc
Boston, Massachusetts, United States
Memorial Sloan Kettering SC - 7
New York, New York, United States
Cincinnati Children s Hospital Medical Center Dept of Oncology
Cincinnati, Ohio, United States
St Jude s Childrens Research Hospital Dept of Oncology
Memphis, Tennessee, United States
Texas Children's Hospital Dept of Oncology
Houston, Texas, United States
Novartis Investigative Site
Randwick, New South Wales, Australia
Start Date
August 28, 2013
Primary Completion Date
April 26, 2019
Completion Date
April 26, 2019
Last Updated
June 9, 2020
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions